Pfizer Approved for Emergency Use of Corona Treatment, Interested in Method, Price, and Side Effects

Pfizer approved for emergency use of coronavirus treatment, interested in how to take, price, and side effects (International News DB)

The Ministry of Food and Drug Safety (MFDS) has decided to approve the emergency use of Pfizer’s edible corona treatment ‘Paxrovid’ in Korea.

This drug is an oral treatment for COVID-19 introduced for the first time in Korea, and the patient takes the pill for five days.

The Ministry of Food and Drug Safety’s decision comes in response to an emergency use authorization request from the Korea Centers for Disease Control and Prevention on the 22nd.

Emergency use authorization is a system in which manufacturers and importers supply unapproved medical products to Korea in order to properly respond to public health crises such as epidemics of infectious diseases.

The Ministry of Food and Drug Safety (MFDS) comprehensively considered the necessity of introducing an edible treatment due to the increase in the number of confirmed COVID-19 cases, the results of safety and effectiveness reviews, and the results of the expert advisory meeting. made a decision

At the advisory meeting, experts agreed that emergency use approval for Paxrovid is necessary in consideration of the domestic COVID-19 pandemic and clinical trial data.

In clinical trials, Paxrovid was found to significantly reduce the risk of hospitalization or death in high-risk mild and moderate COVID-19 patients.

Paxrobead is a treatment for COVID-19 that inhibits virus proliferation by preventing the production of proteins necessary for virus replication. Two tablets are packaged together and can be stored at room temperature.

This drug is prescribed for adults with mild to moderate disease and children 12 years of age and older with COVID-19 who are at high risk of progression to severe disease.

One dose of this drug consists of two tablets of ‘Nirmatrelvir’ and one tablet of ‘ritonavir’.

Patients only need to take two doses per day for five days.

After diagnosis of COVID-19, the drug should be administered as soon as possible within five days of the onset of symptoms.

However, pregnant women are supposed to administer it when the benefits outweigh the risks, and nursing mothers should stop breast-feeding after administering the drug.

The Ministry of Food and Drug Safety expects that it will be effective for patients infected with various mutated COVID-19 viruses, including Omicron, due to the nature of Paxrobead, which inhibits virus proliferation in the body.

Some predicted that the target would be limited due to supply or price.


Leave a Reply

Your email address will not be published. Required fields are marked *